This was accompanied by lower expression levels of the exhaustion markers programmed cell death protein 1 (PD-1) and CD39, strengthening the role of CD73 as an immune checkpoint and as a potential target in tumor therapy. The gene discussed is PDCD1; the disease is neoplasm.